Metastatic Soft Tissue Sarcoma: What to Ask

Soft tissue sarcoma is not one illness. It is a large family of tumors. They are unrelated to each other. They share only a starting place, in connective tissue.

That has a strange consequence, and NCI states it directly. Staging is primarily used as a research tool. It does not routinely drive decisions beyond four things. The subtype. The grade. Where the tumor started. And how far it has gone.

So the first question is not "what stage." It is "what exactly is this."

The evidence on where treatment happens is unusually clear.

NCI reports a Swedish series of 375 patients. Local recurrence was 45 percent in people never referred to a specialist center. It was 24 percent in those referred after a first operation or biopsy. It was 18 percent in those referred before any surgery at all.

A British series of 260 patients found the same pattern from another angle. Local recurrence was 19 percent at the specialist center. Across 38 district hospitals it was 39 percent. And the district tumors were smaller and of lower grade. Patients at the specialist center also had a small survival advantage on multivariate analysis.

Grade is worth asking about by name. The AJCC recommends the three-tier FNCLCC system. Three things are scored. How closely the tumor resembles normal tissue. How fast the cells divide. And how much of the tumor has died off. NCI says the point of that score is to predict who will develop metastasis.

Most sarcomas do not travel through lymph nodes. They travel through the blood, and they land in the lung.

NCI calls the lung the most common site of distant spread. It recommends chest CT for high-grade sarcoma to look there. It also names the exceptions. PET is useful for the subtypes that do favor lymph nodes. Those are synovial sarcoma, clear cell sarcoma, angiosarcoma, rhabdomyosarcoma and epithelioid sarcoma.

That is worth knowing when a scan is ordered. Where the team looks depends on which sarcoma this is.

This page covers adult soft tissue sarcoma, which is the population NCI's stage IV evidence comes from. Bone sarcomas such as osteosarcoma and Ewing sarcoma are treated on entirely different protocols, so if that is your diagnosis, ask your team for guidance written for it.

NCI lists three families of option for stage IV disease. Chemotherapy. Histology-specific targeted or immunotherapy treatment. And surgery.

Doxorubicin has been the standard systemic drug for decades. NCI names the others with activity. They are ifosfamide, epirubicin, pegylated liposomal doxorubicin, gemcitabine, trabectedin, eribulin, pazopanib, dacarbazine and the taxanes.

Then it makes a point that surprises people. Combining anthracyclines raises response rates. It also raises toxicity markedly, without improving overall survival, except in some specific subtypes. So NCI prefers single agents used one after another, in most settings. Adding ifosfamide raises response rate and progression-free survival. It has not been shown to lengthen life. Adding trabectedin to doxorubicin does improve progression-free survival. That applies in metastatic or unresectable leiomyosarcoma.

Gemcitabine with docetaxel is one of several regimens NCI lists for second line and beyond, alongside ifosfamide, trabectedin, eribulin, pazopanib, dacarbazine and pegylated liposomal doxorubicin. Which one comes next depends heavily on your subtype. One randomized phase II study enrolled 122 patients. The response rate was 16 percent, against 8 percent for gemcitabine alone. Median progression-free survival was 6.2 months against 3.0. Median overall survival was 17.9 months against 11.5. But the GeDDis trial put it head to head with doxorubicin in 257 untreated patients. Progression-free survival came out identical.

This is the table worth photographing. NCI lists sarcoma subtypes with higher sensitivity to particular agents:

• Alveolar soft-part sarcoma: kinase inhibitors including sunitinib and pazopanib. Also immunotherapy, including atezolizumab and pembrolizumab.
• Angiosarcoma: taxanes.
• Dermatofibrosarcoma protuberans: imatinib.
• Inflammatory myofibroblastic tumor: ALK inhibitors.
• PEComa: mTOR inhibitors, including nab-sirolimus.
• Sarcomas with an NTRK fusion: larotrectinib.
• Epithelioid sarcoma: tazemetostat.
• Desmoid tumor: nirogacestat, or the kinase inhibitor sorafenib. Desmoid tumors sit slightly apart from the rest of this page. They can grow into nearby tissue and come back locally, but they do not spread to distant organs, so "metastatic" does not apply to them.

Synovial sarcoma has its own route, and it is often described wrongly. The T-cell therapy afamitresgene autoleucel is directed against MAGE-A4. It is not aimed at the SS18-SSX fusion that defines the diagnosis. The label sets several conditions. The disease must be unresectable or metastatic. Chemotherapy must have come first. The patient must be 12 or older. They must carry one of four specific HLA-A02 types. And a companion test must confirm MAGE-A4. It carries a boxed warning for cytokine release syndrome. And it must not be used in anyone carrying HLA-A02:05P. Two separate tests decide eligibility, and neither is the diagnostic fusion. Biomarker testing is doing real work here.

Removing metastases is not routine. It is not fringe either.

NCI's position is careful. Removing lung metastases may bring long-term disease-free survival, if the primary tumor is under control. That applies to favorable disease biology. In NCI's words, that means few nodules and slow growth. NCI then adds the caveat honestly. It is unclear how much of the benefit comes from the operation. It may come instead from choosing patients whose disease was already gentle.

Retroperitoneal sarcoma is the harder case. NCI notes that complete removal is often difficult. These tumors are large by the time they are found. And they sit among structures that cannot be sacrificed freely.

• What is the exact subtype, and who reviewed the slides?
• What is the FNCLCC grade, and which component drove it?
• Is my subtype one of the eight in NCI's table with a matched agent?
• Was molecular testing sent, including NTRK fusion testing?
• Is doxorubicin first here, or does my subtype justify starting elsewhere?
• If the disease is only in my lungs, is removing the nodules being considered?
• Which trial would be the alternative to standard chemotherapy right now?

• Call 911 or go to an emergency department if you cough up blood, or breathlessness or chest pain comes on suddenly. The lung is the commonest site sarcoma spreads to, so a new chest symptom is checked rather than watched.
• Phone your sarcoma team the moment it happens, at any hour, if you have a temperature of 100.5°F — 38 °C is 100.4 °F; act at 100.4 °F — or higher, the threshold CDC gives, or shaking chills, during chemotherapy. Doxorubicin and its relatives strip out the white cells that hold infection down, and an untreated fever in that window can tip into sepsis within hours. Insist on speaking to someone now; if you cannot, go to an emergency department and tell them you are on chemotherapy. After afamitresgene autoleucel, fever, chills, low blood pressure or confusion can mean cytokine release syndrome, which carries a boxed warning and needs treating at once.
• Call your care team the same day if you are breathless lying flat, your ankles swell, or your heart races. Doxorubicin and epirubicin can weaken the heart muscle.
• Call your care team within a day or two if a known lump grows noticeably, a new lump appears, or a limb aches deeply at night. Sarcomas can double in size over weeks, and scan timing may need moving forward.

For the wider picture, see sarcoma and getting a second opinion.

• National Cancer Institute — Soft Tissue Sarcoma Treatment (PDQ®), Health Professional Version
• DailyMed (NIH) — TECELRA (afamitresgene autoleucel) prescribing information
• NCI — Infection and Neutropenia During Cancer Treatment